Notably, our results suggest that blocking the CDH6–integrin interaction with either RGD‐specific mAbs or αIIbβ3 integrin inhibitors represents a promising therapeutic strategy for treating ovarian and renal cancer metastasis. The gene discussed is CDH6; the disease is renal carcinoma.